today announced that it has entered into a definitive agreement with a single healthcare dedicated institutional investor for the purchase and sale of 7,826,087 shares of Aytu's common stock (or common stock equivalent), at a purchase price of $1. 59M, and float is at 54. The gross proceeds to Aytu from this offering are expected to be approximately $20 million, before deducting the placement agent's fees and other offering expenses payable by Aytu. 15 per share, in a registered direct offering priced at-the-market under Nasdaq rules. Institutional investors Altium Capital and Armistice Capital jointly participated in the financing. 8 million shares priced at $1. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 13 institutional holders increased their position in Aytu BioScience Inc. com), a national securities litigation firm, is investigating Aytu BioScience, Inc. (the "Company") entered into a securities purchase agreement (the "Purchase Agreement") with certain institutional investors (the "Purchasers"), pursuant to which the Company agreed to sell and issue, in a registered direct offering, an aggregate of (i) 12,539,197 shares of the Company's. (NASDAQ:AYTU) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. 37 percent to ratify at $0. The total Institutional investors and hedge funds own 77. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the Company's entry into the $3 billion cough and cold market with an exclusive license of FDA-approved Tuzistra. Other hedge funds and other institutional investors also recently modified their holdings of the company. Redwood Mortgage Investors IX,0001448038,6500 Institutional Investor. Aytu Bioscience (NASDAQ:AYTU) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a report issued on Monday, ValuEngine reports. The purpose of this merger is to focus on development of Qualigen’s nanotechnology therapies for the treatment of cancer and infectious diseases. This upgrade is essentially a reflection of an upward trend in earnings. Investors who purchased Aytu shares should contact Block & Leviton for a free case evaluation. 27 institutions hold shares in Aytu BioScience Inc. In another most recent transaction, which held on 3/31/2020, SIGMA PLANNING CORP. Positions in Aytu BioScience Inc. 's portfolio, making the stock its 14th largest […]. 00 price objective for the company in a report on Wednesday, […]. The aggregate market value of the registrant’s common stock, $0. Trading at less than cash value, AYTU has three FDA-approved drugs on the market. Aytu Bioscience, Inc. HONG KONG, Jan 7, 2020 - (ACN Newswire) - Institutional Capital Advisory (Asia) Limited ("ICA"), a leading Asia-based capital markets advisory firm, announced today eight key corporate acces. ENGLEWOOD, CO / ACCESSWIRE / March 11, 2020 / Aytu BioScience, Inc. Finally, this past year we added two exceptional board members in Steve Boyd and Ketan Mehta. 8 million shares priced at $1. Aytu BioScience Inc. It appears that more than several institutional investors and hedge funds decided to increase stakes in AYTU in the recent period. In another most recent transaction, which held on 3/31/2020, SIGMA PLANNING CORP. (AYTU) Top Institutional Holders 29 institutions hold shares in Aytu BioScience Inc. In addition, the Company is also in active discussions with Aytu Biosciences (AYTU), a marketer of a COVID-19 IgG/IgM Rapid Test, and Henry Schein Medical (HSIC), the developer of the Standard Q COVID-19 test, to deploy their respective rapid antibody blood testing solutions. (NYSE:DHR) by 0. Live Discussion of AYTU: Earnings Alert Thursday, May 7, 2020 03/2020 Results. Ended the day down 34. Target Price of the company Aytu BioScience, Inc. Institutional Investors include all hedge. The investor warrant exercises and decrease in our stock price from $4. Clients of the firm include a global institutional investor base domiciled in North America, Europe and Asia. ENGLEWOOD, CO / ACCESSWIRE / October 14, 2019 / Aytu BioScience, Inc. 18 Active Energy Group PLC, Castleton Technology PLC, Columbus McKinnon, Emblaze Ltd. Its broker-dealer subsidiary, Charles Schwab & Co. ENGLEWOOD, CO / ACCESSWIRE / October 14, 2019 / Aytu BioScience, Inc. 77 percent to ratify at $107. 66 million shares of United States Steel Corporation, or 5. The Company will have the right, in its sole discretion, to sell to Lincoln Park up to $25. Business Wire. Institutional Investors include all hedge. 38% of Nektar Therapeutics worth $14,530,000 as of its most recent SEC filing. Tiberend Strategic Advisors is a full-service corporate communications firm specializing in developing strategic communications programs for publicly traded companies as well as for private and emerging growth companies. 59M, and float is at 54. Aytu Bioscience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, is pleased to announce that it has entered into definitive agreements with two institutional investors for the purchase and sale in a. is a brand of TransCanada Co. com, for 90 days. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. In the chart below, we can see that institutions don't own many shares in the company. Apr-22-20 08:25AM : Top Oil and Gas Penny Stocks for Q2 2020 Investopedia: 06:00AM : Clean Energy Launches Online Tool to Calculate Costs of Switching from Diesel to Natural Gas V. Its banking subsidiary, Charles Schwab Bank (member. com), a national securities litigation firm, is investigating Aytu BioScience, Inc. Virtu Financial LLC owned approximately 0. Apollo-Backed EP Energy Files for Bankruptcy After Struggling Under Buyout Debt The Apollo-led investment group that acquired the oil company in 2012 recouped a portion of their cash soon after. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase and sale. Aytu BioScience, Inc today announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase and sale of an aggregate 16,000,000. The stock had previously closed at $1. The institutional investor purchased 29,887 shares of the company’s stock, valued at approximately $36,000. Aytu BioScience Inc. Market Data is delayed by 15 minutes and is for informational and/or educational purposes only. 15 apiece with an unnamed healthcare-focused institutional investor. 4 thousand shares of Aytu BioScience Inc. The Aytu BioScience special meeting is scheduled for February 13, 2020 at 10:00 AM Mountain Time. com), a national securities litigation firm, is investigating Aytu BioScience, Inc. AYTU is producing tangible results with real, revenue-generating products. Now you can follow the best of them with one click! Sell-side analysts work for a brokerage firm and evaluate companies based on various investment criteria typically recommending to Buy, Sell, or Hold a stock. 27 million shares. 77 percent to ratify at $107. BOSTON, April 17, 2020 (GLOBE NEWSWIRE) — Block & Leviton LLP (www. 00% of the company's stock. View institutional ownership trends for Aytu Bioscience. 24% while institutional investors hold 12. Virtu Financial LLC owned 0. It appears that more than several institutional investors and hedge funds decided to increase stakes in AYTU in the recent period. Retail investors can apply in the retail or non-institutional investor category from Nov 8, 2017 to Nov 10, 2017. 0 million shares of the stock in a transaction took place on 3/12/2020. 77M, and float is at 56. This transaction changed our ownership from 81. It focuses on hypogonadism, prostate cancer, urinary tract infections, and male infertility. Aytu BioScience, Inc. Apr-22-20 08:25AM : Top Oil and Gas Penny Stocks for Q2 2020 Investopedia: 06:00AM : Clean Energy Launches Online Tool to Calculate Costs of Switching from Diesel to Natural Gas V. KS: KR MOTORS. ENGLEWOOD, CO / ACCESSWIRE / March 12, 2020 / Aytu BioScience, Inc. 0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. New Age Beverages Corporation (NASDAQ: NBEV) the Colorado-based leading all-natural and organic healthy functional beverage company today announced that the Company has been invited to present at Maxim Group's Innovative Leaders in Beverage Institutional Investor Conference to be held on Thursday, November 9th 2017. 07% compared to the previous one. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. 59M, and float is at 54. (KMPH)’s share price decreased by -7. 8 million shares priced at $1. AYTU has attracted considerable attention from traders and investors, a scenario that has seen its volume drop -71. Pre-Funded Warrants offered by us pursuant to this prospectus We are also offering to an institutional investor, Pre-Funded Warrants to purchase up to supplement 3,376,087 shares of common stock. If you have additional questions, please call Investor Relations on 212-492- 1110. Positions in Aytu BioScience Inc. com), a national securities litigation firm, is investigating Aytu BioScience, Inc. 44M shares held by insiders accounting for 6. The firm represents many of the nation's largest institutional investors as well as individual investors in securities litigation throughout the United States. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. public company focused on the treatment of ophthalmic disorders company, in a private placement with institutional and accredited investors of 3,100,000 shares of common. The institutional investor owned 2,080,504 shares of the company's stock after purchasing an additional 22,752 shares during the period. 37 percent to ratify at $0. your username. Trading at less than cash value, AYTU has three FDA-approved drugs on the market. Press Release – New York, NY – March 6, 2018 – Sichenzia Ross Ference Kesner LLP announced today that it has represented AYTU Bioscience, Inc. Pre-Funded Warrants offered by us pursuant to this prospectus We are also offering to an institutional investor, Pre-Funded Warrants to purchase up to supplement 3,376,087 shares of common stock. (OTCQX: AYTU) ("Aytu"), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, announced today that it has entered into a $10. Nwam LLC boosted its stake in Maiden Holdings, Ltd. Company insiders that own Aytu Bioscience stock include Armistice Capital Master Fund, David A Green and Joshua R Disbrow. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that it has entered into a definitive agreement with a single healthcare dedicated institutional investor for the purchase and sale of 7,826,087 shares of Aytu’s common stock (or common stock equivalent), at a purchase price of $1. Here is a quick look at four such penny stocks. Aytu BioScience, Inc. listed on the stock exchange. 's Annual Report on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time. 49% during the last quarter. 34, with a volume of 5,954,324 shares traded. 56, with a volume of 9,828,269 shares traded. Aytu BioScience (NASDAQ: AYTU) inks agreements with several institutional investors for the direct sale of 16M common shares and one-year warrants to purchase up to 16M common shares at $1. See all shares markets. Trading at less than cash value, AYTU has three FDA-approved drugs on the market. 0 million of, (i) shares of the Company's Series F Convertible (the "Preferred Stock") which are. (NYSE:DHR) by 0. com), a national securities litigation firm, is investigating Aytu BioScience, Inc. Shares of Aytu Bioscience Inc (NASDAQ:AYTU) gapped down before the market opened on Wednesday. 77 percent to ratify at $107. In January 2016, we distributed a majority of our shares of common stock of Aytu to our shareholders on a pro rata basis. The shares outstanding are 60. In May and October of 2016, Aytu completed offerings which were dilutive to the Aytu shares we held. bought approximately 15. Following that, we were successful in attracting two reputable Wall Street healthcare analysts from Ladenburg Thallman and Northland Securities. (KALA)'s share price increased by 6. 19 this now indicates there is a potential upside of 215. 77M, and float is at 56. and institutional investors. An institutional investor recently bought a new position in Aytu Bioscience stock. The firm bought 744,695 shares during the quarter which increased its stakes to 4,021,135 shares and is now valued at $35,225,143. The total Institutional investors and hedge funds own 77. In another most recent transaction, which held on 3/31/2020, SIGMA PLANNING CORP. (AYTU) Top Institutional Holders 29 institutions hold shares in Aytu BioScience Inc. On October 11, 2019, Aytu BioScience, Inc. 04 million shares. The total Institutional investors and hedge funds own 14. 99% to hit a new 52-week low, while the S&P 500 index fell 9. 2019-11-15 seekingalpha. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 13 institutional holders increased their position in Aytu BioScience Inc. BOSTON, April 17, 2020 (GLOBE NEWSWIRE) — Block & Leviton LLP (www. Virtu Financial LLC bought a new stake in shares of Aytu Bioscience Inc (NASDAQ:AYTU) in the 3rd quarter. Peter Sands-- Director, Institutional Investor Relations. (NASDAQ: AYTU) and certain of its. 80% of the company’s stock. Institutional investors and hedge funds own 30. 0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. Almost as bad as Susquehannah. (AYTU), as it has been recently upgraded to a Zacks Rank #2 (Buy). 37 percent to ratify at $0. 24% while institutional investors hold 12. com), a national securities litigation firm, is investigating Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that it has entered into a definitive agreement with a single healthcare dedicated institutional investor for the purchase and sale of 7,826,087 shares of Aytu's common stock (or. Back on the stock side of things, we have spotted a big news play on the OTC Market in VYST. Following these latest developments, around 0. Aytu BioScience is not a large company by global standards. 36, but opened at $1. and institutional investors. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the Company's entry into the $3 billion cough and cold market with an exclusive license of FDA-approved Tuzistra. The purpose of this merger is to focus on development of Qualigen's nanotechnology therapies for the treatment of cancer and infectious diseases. com Newswire) Coronavirus / Pharma (COVID-19) Stock News Bites: Aytu BioScience, Inc. 5 million common stock purchase agreement with Lincoln Park Capital Fund, LLC ("LPC"), a Chicago-based institutional investor. Both the retail trading class and the institutional investors that follow the more than $2 billion TRT opportunity should realize that ATRS’s troubles will act as yet another market catalyst for. The biggest gainers of the session on the Dow Jones Industrial Average were Intel. Separately, Zacks Investment Research raised Aytu Bioscience from a “hold” rating to a “buy” rating and set a $1. A total of 19,520,000. Seanergy Maritime (SHIP)'s direct offering of $6. com), a national securities litigation firm, is investigating Aytu BioScience, Inc. 's Annual Report on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time. (LOW)’s share price increased by 2. In the most recent purchasing and selling session, KemPharm Inc. Block & Leviton LLP is a firm dedicated to representing investors and maintaining the integrity of the country's financial markets. 15 per share, in a registered direct offering. 24% while institutional investors hold 12. (AYTU), as it has been recently upgraded to a Zacks Rank #2 (Buy). (AYTU), with 2. Aytu BioScience, Inc. Pursuant to the Aytu Purchase Agreement, Aytu assumed sales returns of the Pediatric Portfolio made after the closing date of November 1, 2019 and primarily relating to sales prior to November 1, 2019 only to the extent such post-Closing sales returns exceed $2. The Fly team scours all sources of company news, from mainstream to cutting edge,then filters out the noise to deliver shortform stories consisting of only market moving content. An upward trend in earnings estimates -- one of the most powerful. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that it has entered into a definitive agreement with a single healthcare dedicated institutional investor for the purchase and sale of 7,826,087 shares of Aytu's common stock (or. Aytu Bioscience, Inc. (AYTU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). This might drive the stock higher in the near term. 15 per share, in a registered direct offering. Aytu Bioscience shares last traded at $1. 90 in a total of its share price and finished its trading at 1. The Nasdaq Biotechnology index was dropping 4. The IPO fund raising was widely supported by the Australian public, a large resources-focused institutional investor and the agricultural community which sees a need to address Australia’s reliance on imported potassium fertilisers, necessary for agricultural production. We can zoom in on the different ownership groups, to learn more about AYTU. Separately, Zacks Investment Research raised Aytu Bioscience from a “hold” rating to a “buy” rating and set a $1. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing. - Dennis Bourgeault to retire after more than 20 years with the company - VICTORIA, British Columbia & ROCKVILLE, Md. The daily trading volume for Aytu BioScience Inc. The Company is in negotiations with the debenture holder and its secured lenders with respect to the Debentures. 8 million shares priced at $1. We also refer you to the risks described in ''Risk Factors'' in Part I, Item 1A of Aytu BioScience, Inc. On March 19, 2020, Aytu BioScience, Inc. That is how Sabby Capital LLC now has an increase position in AYTU by 55,337. Aytu BioScience is not a large company by global standards. The mentioned changes placed institutional holdings at 8,512,340 shares, according to the latest SEC report filing. In depth view into Aytu BioScience Year to Date Price Returns (Daily) including historical data from 2008, charts, stats and industry comps. 59M, and float is at 54. On March 10, 2020, Aytu BioScience, Inc. Calculated from current quarterly filing as of today. (KMPH)’s share price decreased by -7. 6, 2016 /PRNewswire/ --Aytu BioScience Inc. com), a national securities litigation firm, is investigating Aytu BioScience, Inc. The daily trading volume for Aytu BioScience Inc. Member FINRA / SIPC. On October 11, 2019, Aytu BioScience, Inc. Members of Institutional Investor’s All- Canada Executive Team discuss the. The securities will be offered only to institutional accredited investors in accordance with Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder. 55M with Short Float at 5. com, for 90 days. Cardinal Capital Management trimmed its holdings in shares of State Street Corp (NYSE:STT) by 2. Retail investors can apply in the retail or non-institutional investor category from Nov 8, 2017 to Nov 10, 2017. That is how Sabby Capital LLC now has an increase position in AYTU by 55,337. Armistice Capital is a global, long/short, value-oriented and event-driven hedge fund focused. Pursuant to the Aytu Purchase Agreement, Aytu assumed sales returns of the Pediatric Portfolio made after the closing date of November 1, 2019 and primarily relating to sales prior to November 1, 2019 only to the extent such post-Closing sales returns exceed $2. (AYTU) Top Institutional Holders. 45, but opened at $1. 73% of the company’s shares. In the most recent purchasing and selling session, Lowe’s Companies Inc. The institutional investor bought 6. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the Company's entry into the $3 billion cough and cold market with an exclusive license of FDA-approved Tuzistra. January 13, Aytu BioScience Obtains CE Marking for Company's MiOXSYS™ System for Male Infertility. 33 million shares at $0. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. 59M, and float is at 54. In January 2016, we distributed a majority of our shares of common stock of Aytu to our shareholders on a pro rata basis. A replay of the call will be available for fourteen days. Aytu Bioscience, Inc. 37 percent to ratify at $0. (NASDAQ: AYTU) and certain of its. ENGLEWOOD, CO / ACCESSWIRE / March 11, 2020 / Aytu BioScience, Inc. Analyze up to 10 years of full 10K Annual Reports and Quarterly 10Q SEC filings for Aytu Bioscience, Inc (AYTU) using our online tools. Members of Institutional Investor’s All- Canada Executive Team discuss the. (the "Company") entered into a securities purchase agreement (the "Purchase Agreement") with an institutional investor (the "Purchaser"), pursuant to which the Company agreed to sell and issue, in a registered direct offering, an aggregate of (i) 4,450,000 shares of the Company's common stock (the. The Company’s 9% convertible unsecured subordinated debentures (the “Debentures“) issued to an institutional investor in the principal amount of $15 million mature on March 27, 2020. 59M, and float is at 54. The daily trading volume for Aytu BioScience Inc. 70% of the company’s stock. 42% of the company's stock. (AYTU) Top Institutional Holders 29 institutions hold shares in Aytu BioScience Inc. Zacks Investment Research raised […]. HONG KONG, Jan 7, 2020 - (ACN Newswire) - Institutional Capital Advisory (Asia) Limited ("ICA"), a leading Asia-based capital markets advisory firm, announced today eight key corporate acces. 38 %: Total Shares Outstanding (millions) 91: Total Value of Holdings (millions) $13. The institutional investor purchased 29,887 shares of the company's stock, valued at approximately $36,000. (AYTU), as it has been recently upgraded to a Zacks Rank #2 (Buy). 33, but opened at $1. (NASDAQ: AYTU) and certain of its. 15 apiece with an unnamed healthcare-focused institutional investor. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase and sale of an aggregate 12,539,187 shares of Aytu's. (AYTU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). pursuant to this prospectus supplement and accompanying prospectus to several institutional investors. (), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase and sale of an aggregate 12,539,187 shares of Aytu's common stock and. 44M shares held by insiders accounting for 6. Armistice was the winner of 2017 US Hedge Fund Performance Awards by HFM for long/short equity, long/short equity long-term performance (5 years) under $1bn, and single manager long-term performance under $1bn. BOSTON, April 17, 2020 (GLOBE NEWSWIRE) — Block & Leviton LLP (www. 's Annual Report on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time. 49% in the first quarter, owning 6 million shares of AYTU stocks, with the value of $9 million after the purchase of an additional. Aytu BioScience, Inc. institutional ownership is held at 20. 00% of the company's stock. The institutional investor owned 673,138 shares of the biopharmaceutical company’s stock after selling 122,782 shares during the period. 36M, and float is at 54. (AYTU), with 1. Aytu Bioscience, Inc. They represent some of the most successful hedge funds in the world. Investors might want to bet on Aytu Bioscience, Inc. (LOW)’s share price increased by 2. Aytu BioScience Inc. 36, but opened at $1. 70% of the company’s stock. 77 percent to ratify at $107. 4 thousand shares of Aytu BioScience Inc. Aytu Bioscience, Inc. AYTU has attracted considerable attention from traders and investors, a scenario that has seen its volume drop -71. January 14, 2020. recorded at $3. AYTU has attracted considerable attention from traders and investors, a scenario that has seen its volume drop -40. (AYTU) is expected to deliver a year-over-year increase in earnings on higher revenues when i t report s results for the quarter ended December 2019. ENGLEWOOD, CO / ACCESSWIRE / March 19, 2020 / Aytu BioScience, Inc. (AYTU) Top Institutional Holders. 15 apiece with an unnamed healthcare-focused institutional investor. Market Snapshot: Dow futures edge back as investors await report that could show total unemployed in U. Press Release - New York, NY - March 6, 2018 - Sichenzia Ross Ference Kesner LLP announced today that it has represented AYTU Bioscience, Inc. Aytu Bioscience Inc (NASDAQ:AYTU)'s stock price gapped up before the market opened on Thursday. 16 in a total of its share price and finished its trading at 1. (AYTU) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). 40 respectively. That is how Sabby Capital LLC now has an increase position in AYTU by 55,337. View and follow the analysts whose ratings consistently outperform the. bought approximately 15. 47 per share. In the most recent purchasing and selling session, Aytu BioScience Inc. 14% of Aytu Bioscience at the end of the most recent quarter. Positions in Aytu BioScience Inc. A total of 19,520,000. Lululemon apologises after staffer offends with 'bat fried rice' T-shirt. Swing trader Original Poster 3 points · 17 days ago. The total Institutional investors and hedge funds own 14. HK: CLP Holdings Ltd. This prospectus supplement also relates to the offering of common stock issuable upon exercise of such Warrants. Several analysts have recently issued reports on the company. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the Company's entry into the $3 billion cough and cold market with an exclusive license of FDA-approved Tuzistra. 80% of the company’s stock. Market Exclusive Sitemap. Description: Aytu BioScience Inc is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. Hedge funds and other institutional investors own 31. For AYTU investors, management has guided toward an achievable goal, which is to place an estimated 200 MiOXSYS® systems worldwide by the end of 2020. It appears that more than several institutional investors and hedge funds decided to increase stakes in AYTU in the recent period. 62M shares held by insiders accounting for 15. 49% during the last quarter. 55M with Short Float at 12. In the most recent purchasing and selling session, Lowe’s Companies Inc. 15 per share, in a registered direct offering priced at-the-market under Nasdaq rules. Daily Mail and General Trust holds more than 49 percent of Euromoney, which provides business-to-business information. We can zoom in on the different ownership groups, to learn more about AYTU. In another most recent transaction, which held on 3/31/2020, SIGMA PLANNING CORP. View institutional ownership trends for Aytu Bioscience. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 13 institutional holders increased their position in Aytu BioScience Inc. (AYTU) Top Institutional Holders. It appears that more than several institutional investors and hedge funds decided to increase stakes in AYTU in the recent period. Tiberend Strategic Advisors is a full-service corporate communications firm specializing in developing strategic communications programs for publicly traded companies as well as for private and emerging growth companies. AYTU : Get atock charts, earnings data, Benzinga ratings and intraday stock tips from independent traders who track AYTU. AYTU is producing tangible results with real, revenue-generating products. 18 percent to ratify at $1. Aytu is a specialty pharmaceutical company focused on global commercialization of products addressing a variety of medical needs. 01 Entry into a Material Definitive Agreement. Armistice was the winner of 2017 US Hedge Fund Performance Awards by HFM for long/short equity, long/short equity long-term performance (5 years) under $1bn, and single manager. AYTU has attracted considerable attention from traders and investors, a scenario that has seen its volume drop -71. For experienced investors that listen to conference calls, they know that small companies always have a reason on hand for missed earnings, lack of capital, slow trials, and a bloating capital structure. (LOW)’s share price increased by 2. 45, but opened at $1. 55M with Short Float at 12. Lululemon apologises after staffer offends with 'bat fried rice' T-shirt. The fund bought 29,887 shares of the company's stock, valued at approximately $36,000. 24% while institutional investors hold 12. 29%, and the NASDAQ Composite index gained 9. 80% of the company’s stock. For AYTU investors, management has guided toward an achievable goal, which is to place an estimated 200 MiOXSYS® systems worldwide by the end of 2020. In another most recent transaction, which held on 3/31/2020, SIGMA PLANNING CORP. Steve is a highly respected investor and founder of. 14% of Aytu Bioscience at the end of the most recent quarter. 0 million shares of the stock in a transaction took place on 3/12/2020. 37 percent to ratify at $0. In the most recent purchasing and selling session, KemPharm Inc. 42% of the company’s stock. On March 10, 2020, Aytu BioScience, Inc. Analyze up to 10 years of full 10K Annual Reports and Quarterly 10Q SEC filings for Aytu Bioscience, Inc (AYTU) using our online tools. This upgrade is essentially a reflection of an upward trend in earnings. 49% in the first quarter, owning 6 million shares of AYTU stocks, with the value of $9 million after the purchase of an additional. At the close in NYSE, the Dow Jones Industrial Average lost 9. bought approximately 15. 04M with Short Float at 1. ENGLEWOOD, Colo. AYTU stock construct a change of -2. In another most recent transaction, which held on 3/31/2020, SIGMA PLANNING CORP. Virtu Financial LLC owned about 0. Aytu BioScience, Inc today announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase and sale of an aggregate 12,539,187. (AYTU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy). (NASDAQ: AYTU) and certain of its. Hedge funds and other institutional investors own 30. Read Modest Money's latest article on Investing. (NYSE:DHR) by 0. This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. This banner text can have markup. A number of equities analysts recently weighed in on the stock. A total of 19,520,000. 50% of the company's stock. (KMPH)’s share price decreased by -7. The daily trading volume for Aytu BioScience Inc. Hedge funds and other institutional investors own 31. Aytu Bioscience shares last traded at $1. public company focused on the treatment of ophthalmic disorders company, in a private placement with institutional and accredited investors of 3,100,000 shares of common. SOHM manufacturing and marketing target the rapidly growing healthcare segments such as Nutraceuticals, Cosmeceuticals,. We can zoom in on the different ownership groups, to learn more about AYTU. 0 million shares of the stock in a transaction took place on 3/12/2020. The total Institutional investors and hedge funds own 77. In the most recent purchasing and selling session, KemPharm Inc. For AYTU investors, management has guided toward an achievable goal, which is to place an estimated 200 MiOXSYS® systems worldwide by the end of 2020. – Sino Biopharm was the only Chinese pharmaceutical company named among Forbes’ “Asia 200 Best Over a Billion 2019”. Back on the stock side of things, we have spotted a big news play on the OTC Market in VYST. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. AYTU investors were disappointed as the stock returned -30. The mentioned changes placed institutional holdings at 8,512,340 shares, according to the latest SEC report filing. The biggest gainers of the session on the Dow Jones Industrial Average were Intel. On March 12, 2020, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company agreed to sell and issue, in a registered direct offering, an aggregate of (i) 16,000,000 shares of the Company’s common stock at a purchase price per share of common stock $1. On March 10, 2020, Aytu BioScience, Inc. The total Institutional investors and hedge funds own 14. 8 billion in assets under management. For experienced investors that listen to conference calls, they know that small companies always have a reason on hand for missed earnings, lack of capital, slow trials, and a bloating capital structure. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support. Hedge funds and other institutional investors own 30. The shares outstanding are 60. Aytu Bioscience Company Profile. 0 million in shares of the Company’s common stock over a 36-month period. Aytu BioScience is not a large company by global standards. (NASDAQ: AYTU) in a $12 million public offering of Class A Units, comprising common stock and warrants and Class B Units comprising Series B Preferred Stock and Warrants. Added multiple high-quality, healthcare focused fundamental institutional investors Added two sell-side analysts covering AYTU Expanded the board to include Steve Boyd, Founder and CIO of healthcare institutional investor Armistice Capital, and Ketan Mehta, Founder, President, and Chief Executive Officer of Tris Pharma. today announced that it has entered into a definitive agreement with a single healthcare dedicated institutional investor for the purchase and sale of 7,826,087 shares of Aytu's common stock (or common stock equivalent), at a purchase price of $1. (NASDAQ: AYTU) and certain of its. (OTCQX: AYTU) ("Aytu"), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, announced today that it has entered into a $10. recorded at $3. Aytu Bioscience shares last traded at $1. 49% in the first quarter, owning 6 million shares of AYTU stocks, with the value of $9 million after the purchase of an additional. belongs to the Others business sector. It appears that more than several institutional investors and hedge funds decided to increase stakes in AYTU in the recent period. A number of research analysts have recently issued reports on AYTU shares. 80% of the company’s stock. Aytu BioScience, Inc today announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase and sale of an aggregate 12,539,187. bought approximately 15. AYTU Should be A Standout. 14% of Aytu Bioscience as of its most recent filing with the Securities & Exchange Commission. 77 percent to ratify at $107. The stock had previously closed at $1. Investors who purchased Aytu shares should contact Block & Leviton for a free case evaluation. Whether investors gauge the momentum by recognizing the spike in product sales or by the growth in new prescribers, AYTU is proving their ability to drive adoption of Natesto® at an accelerated. Aytu BioScience is pursuing an emergency use authorization with the FDA for the COVID-19 IgG/IgM test. Morning Brief: Marcato Liquidates Deckers Stake The activist hedge fund manager has sold its shares in the UGG maker after losing its proxy fight last year. Investors with an interest in Medical stocks should continue to track AYTU. In the most recent purchasing and selling session, Kala Pharmaceuticals Inc. Both the retail trading class and the institutional investors that follow the more than $2 billion TRT opportunity should realize that ATRS’s troubles will act as yet another market catalyst for. The total Institutional investors and hedge funds own 14. 14% of Aytu Bioscience at the end of the most recent quarter. In the most recent purchasing and selling session, Lowe’s Companies Inc. (NASDAQ: AYTU) and certain of its. 10 stocks we like better than AT&T When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. 24% while institutional investors hold 12. In certain circumstances, securities with respect to which the relevant exchange has commenced delisting proceedings may continue to be traded pending appeal of that determination. Target Price of the company Aytu BioScience, Inc. 8% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). AYTU Stock Message Board: An institutional investor is buying 9 million share. See why Aytu BioScience (AYTU) investor sentiment is more positive in comparison to other stocks in the Services sector. TipRanks measures and ranks experts based on their performance. The COVID-19 IgG/IgM is a rapid test intended for the presumptive qualitative detection of IgG/IgM antibodies from the 2019-nCoV in blood samples from individuals with signs and symptoms of infection who are suspected of Sars Cov-2. The shares outstanding are 65. (AYTU), with 1. 8 million shares priced at $1. (LOW)’s share price increased by 2. 9% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). Aytu BioScience Inc is a specialty pharmaceutical company commercializing novel products addressing patient needs. 0 Million Registered Direct Offering Priced At-the-Market. bought approximately 15. Detailed company description & address for Canopy Growth Corp. Member FINRA / SIPC. See the complete profile on LinkedIn and discover Matt’s. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The stock had previously closed at $1. About Aytu BioScience. 70% of the company’s stock. 0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. [NASDAQ:AYTU] by around 2,945,240 shares. Aytu BioScience with ticker code (AYTU) now have 2 analysts covering the stock. Aytu BioScience Inc. Here is a quick look at four such penny stocks. 03%) and HCR Wealth Advisors (0. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. Market Snapshot: Dow futures edge back as investors await report that could show total unemployed in U. 24% while institutional investors hold 12. Institutional Investors 0 See All. gov and on Aytu BioScience's website in the Investor section. On February 10, 2020, the company announced that it had entered into an equity line purchase agreement with Lincoln Park Capital Fund, LLC a Chicago-based institutional investor. (the "Company") entered into Securities Purchase Agreements (the "Purchase Agreement") with two institutional accredited investors (the "Investors") providing for the issuance and sale by the Company (the "Offering") of $10. View institutional ownership trends for Aytu Bioscience. 48% above Q4 High. [NASDAQ:AYTU] by around 2,945,240 shares. 24% while institutional investors hold 12. Aytu BioScience (NASDAQ:AYTU) inks agreements with several institutional investors for the direct sale of 16M common shares and one-year warrants to purchase up to 16M common shares at $1. Positions in Aytu BioScience Inc. ENGLEWOOD, CO / ACCESSWIRE / March 11, 2020 / Aytu BioScience, Inc. 36, but opened at $1. What are institutional investors and what other kinds of investors are there. Contact for Investors: James Carbonara Hayden IR (646)-755-7412 [email protected]. Redwood Mortgage Investors IX,0001448038,6500 Institutional Investor. 44M shares held by insiders accounting for 6. AYTU stock had 4 new institutional investments in for a total of 4 shares, while 6 institutional investors sold positions of 196,093 shares during the same period. The total Institutional investors and hedge funds own 14. (AYTU), with 1. 49% in the first quarter, owning 6 million shares of AYTU stocks, with the value of $9 million after the purchase of an additional. 00 price objective for the company in a report on Wednesday, […]. 34, with a volume of 5,954,324 shares traded. 80% of the company’s stock. The institutional investor bought 18,571 shares of the company’s stock, valued at approximately $1,060,000. January 13, Aytu BioScience Obtains CE Marking for Company's MiOXSYS™ System for Male Infertility. It appears that more than several institutional investors and hedge funds decided to increase stakes in AYTU in the recent period. Which institutional investors are buying and selling shares of Aytu Bioscience (NASDAQ:AYTU) stock? View the most recent institutional ownership activity and 13F transactions for AYTU stock at MarketBeat. 59M, and float is at 54. Institutional and Fund Ownership - Buyers Major holders that have opened new positions in AYTU / Aytu BioScience, Inc. bought approximately 15. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase and sale of an aggregate 16,000,000 shares of Aytu's common. ENGLEWOOD, Colo. BOSTON, April 17, 2020 (GLOBE NEWSWIRE) — Block & Leviton LLP (www. Aytu Announces $9. 07% compared to the previous one. The gross proceeds to Aytu from this offering are expected to be approximately $9. com), a national securities litigation firm, is investigating Aytu BioScience, Inc. Credit Suisse AG owned about 0. Contact for Investors: James Carbonara. As of now, AYTU has a P/S, P/E and P/B values of 10. January 14, 2020. 5 with a mean TP of 3. Market Exclusive Sitemap. The webcast will be accessible live and archived on Aytu BioScience's website, within the Investors section under Events & Presentations, at aytubio. 59M, and float is at 54. The institutional investor purchased 29,887 shares of the company's stock, valued at approximately $36,000. ENGLEWOOD, CO / ACCESSWIRE / March 19, 2020 / Aytu BioScience, Inc. Nothing is guaranteed though, especially with the current market conditions. BOSTON, April 17, 2020 (GLOBE NEWSWIRE) — Block & Leviton LLP (www. 's Annual Report on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time. Institutional Investors include all hedge. Aytu BioScience is not a large company by global standards. AYTU stock construct a change of -3. (AYTU) and certain of its officers for potential securities fraud. Apollo-Backed EP Energy Files for Bankruptcy After Struggling Under Buyout Debt The Apollo-led investment group that acquired the oil company in 2012 recouped a portion of their cash soon after. However, it looks like Sabby does their due diligence. 37M shares. It appears that more than several institutional investors and hedge funds decided to increase stakes in AYTU in the recent period. These institutions hold a total of 695,204 shares. For AYTU investors, management has guided toward an achievable goal, which is to place an estimated 200 MiOXSYS® systems worldwide by the end of 2020. 29 institutions hold shares in Aytu BioScience Inc. 03%) and HCR Wealth Advisors (0. 25 and (ii) warrants to. A total of 19,520,000. (NYSE:DHR) by 0. That is how Sabby Capital LLC now has an increase position in AYTU by 55,337. Son code de société cotée dit ISIN est SE0009241706. (-) Aytu BioScience (AYTU) slumped Wednesday, dropping over 34% and reversing a nearly 20% advance for the specialty drugmaker that followed the company earlier announcing a $9 million at-the-market direct offering of more than 7. The fund bought 29,887 shares of the company's stock, valued at approximately $36,000. , Wealthcare Advisory Partners LLC, Anfield Capital Management, LLC, and Verus Capital Partners, Llc. Aytu BioScience Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor (the “Purchaser”), pursuant to which the Company agreed to sell and issue, in a registered direct offering, an aggregate of (i) 4,450,000 shares of the Company’s common. Both the retail trading class and the institutional investors that follow the more than $2 billion TRT opportunity should realize that ATRS’s troubles will act as yet another market catalyst for. 18 percent to ratify at $1. (LOW)’s share price increased by 2. 49% in the first quarter, owning 6 million shares of AYTU stocks, with the value of $9 million after the purchase of an additional. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. (the "Company") entered into Securities Purchase Agreements (the "Purchase Agreement") with two institutional accredited investors (the "Investors") providing for the issuance and sale by the Company (the "Offering") of $10. Daily Mail and General Trust holds more than 49 percent of Euromoney, which provides business-to-business information. The shares outstanding are 56. Aytu BioScience Inc. com Newswire) Coronavirus / Pharma (COVID-19) Stock News Bites: Aytu BioScience, Inc. BOSTON, April 17, 2020 (GLOBE NEWSWIRE) -- Block & Leviton LLP (www. 00% of the company's stock. 59M, and float is at 54. 18 percent to ratify at $1. In the chart below below, we can see that institutions don't own many shares in the company. and institutional investors. For more information, please visit www. stock-index futures pointed to a slight pullback for Thursday after strong gains in regular trade Wednesday, as investors braced for an updated report. I generally like to see some degree of insider ownership, even if only a little. Virtu Financial LLC bought a new stake in shares of Aytu Bioscience Inc (NASDAQ:AYTU) in the 3rd quarter. Pursuant to the Aytu Purchase Agreement, Aytu assumed sales returns of the Pediatric Portfolio made after the closing date of November 1, 2019 and primarily relating to sales prior to November 1, 2019 only to the extent such post-Closing sales returns exceed $2. 38 %: Total Shares Outstanding (millions) 91: Total Value of Holdings (millions) $13. Its broker-dealer subsidiary, Charles Schwab & Co. businesses — and how they plan to rise above them. Detailed company description & address for Canopy Growth Corp. 59M, and float is at 54. for three years, with three year auto-renewals thereafter. Aytu Bioscience Company Profile. Nächsten Hauptversammlungstermine On July 21,2018 23. 29 institutions hold shares in Aytu BioScience Inc. (AYTU) Top Institutional Holders 29 institutions hold shares in Aytu BioScience Inc. BOSTON, April 17, 2020 (GLOBE NEWSWIRE) — Block & Leviton LLP (www. 24% while institutional investors hold 12. 14% of Aytu Bioscience as of its most recent filing with the Securities & Exchange Commission. Aytu BioScience with ticker code (AYTU) now have 2 analysts covering the stock. (LOW)’s share price increased by 2. ST Invest is a wholly owned subsidiary of StockTwits, Inc. About Aytu Bioscience (NASDAQ:AYTU) Aytu BioScience, Inc, a specialty healthcare company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), insomnia, and male infertility in the United States and. Searle & CO. (AYTU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). ENGLEWOOD, CO & SAN DIEGO, CA / ACCESSWIRE / January 27, 2020 /Aytu BioScience, Inc. Several analysts have recently issued reports on the company. 97 percent to ratify at $9. An institutional investor recently raised its position in Aytu Bioscience stock.